This “Nasopharyngeal Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Nasopharyngeal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the nasopharynx, the upper part of the throat behind the nose and near the base of skull. In early cases Nasopharyngeal cancer may not cause any symptoms. The possible symptoms may include: lump in neck, blood in saliva, frequent ear infections, sore throat, nasal congestion, hearing loss. Tests and procedures used to diagnose nasopharyngeal carcinoma include: physical exam, nasal endoscopy and biopsy. Treatment for nasopharyngeal carcinoma usually begins with radiation therapy or a combination of radiation and chemotherapy.
"Nasopharyngeal Cancer - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nasopharyngeal Cancer pipeline landscape is provided which includes the disease overview and Nasopharyngeal Cancer treatment guidelines. The assessment part of the report embraces, in depth Nasopharyngeal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nasopharyngeal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence R&D. Nasopharyngeal Cancer The therapies under development are focused on novel approaches to treat/improve Nasopharyngeal Cancer.
This segment of the Nasopharyngeal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sintililimab: Innovent Biologics (Suzhou) Co. Ltd.
Sintilimab, a highly selective fully human IgG4 monoclonal antibody, blocks the binding site of programmed cell death protein 1 (PD-1), thereby, inhibiting the interaction between PD-1 and its ligands (PD-L1/2) to restore the endogenous anti-tumor T cell responses. The clinical trials for sintilimab are being evaluated for the treatment of Nasopharyngeal Neoplasms in phase III stage of development.
Tislelizumab: BioGene
Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R on macrophages. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. It is being studied in phase III stage of development for the treatment of Recurrent or Metastatic Nasopharyngeal Cancer.
Tabelecleucel: Atara Biotherapeutics Inc.
Tabelecleucel, tab-cel® is an off-the-shelf, allogeneic T-cell immunotherapy in phase I/II studies for the treatment of nasopharyngeal carcinoma.
PDR001: Novartis Pharmaceuticals
PDR001 (anti-PD-1) is an investigational immunotherapy being developed by Novartis to treat both solid tumors and lymphomas. PDR001 is a type of immunotherapy, it acts by activating the body's own immune system to recognize and fight cancer cells. The drug is being studied in phase II stage of development for the treatment of Nasopharyngeal cancer.
There are approx. 10+ key companies which are developing the therapies for NASOPHARYNGEAL CANCER. The companies which have their Nasopharyngeal Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.
Route of Administration
Molecule Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nasopharyngeal Cancer therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nasopharyngeal Cancer drugs.
Geography Covered
- Global coverage
Nasopharyngeal Cancer Understanding
Nasopharyngeal Cancer: Overview
Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the nasopharynx, the upper part of the throat behind the nose and near the base of skull. In early cases Nasopharyngeal cancer may not cause any symptoms. The possible symptoms may include: lump in neck, blood in saliva, frequent ear infections, sore throat, nasal congestion, hearing loss. Tests and procedures used to diagnose nasopharyngeal carcinoma include: physical exam, nasal endoscopy and biopsy. Treatment for nasopharyngeal carcinoma usually begins with radiation therapy or a combination of radiation and chemotherapy.
"Nasopharyngeal Cancer - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nasopharyngeal Cancer pipeline landscape is provided which includes the disease overview and Nasopharyngeal Cancer treatment guidelines. The assessment part of the report embraces, in depth Nasopharyngeal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nasopharyngeal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence R&D. Nasopharyngeal Cancer The therapies under development are focused on novel approaches to treat/improve Nasopharyngeal Cancer.
NASOPHARYNGEAL CANCER Emerging Drugs Chapters
This segment of the Nasopharyngeal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nasopharyngeal Cancer Emerging Drugs
Sintililimab: Innovent Biologics (Suzhou) Co. Ltd.
Sintilimab, a highly selective fully human IgG4 monoclonal antibody, blocks the binding site of programmed cell death protein 1 (PD-1), thereby, inhibiting the interaction between PD-1 and its ligands (PD-L1/2) to restore the endogenous anti-tumor T cell responses. The clinical trials for sintilimab are being evaluated for the treatment of Nasopharyngeal Neoplasms in phase III stage of development.
Tislelizumab: BioGene
Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R on macrophages. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. It is being studied in phase III stage of development for the treatment of Recurrent or Metastatic Nasopharyngeal Cancer.
Tabelecleucel: Atara Biotherapeutics Inc.
Tabelecleucel, tab-cel® is an off-the-shelf, allogeneic T-cell immunotherapy in phase I/II studies for the treatment of nasopharyngeal carcinoma.
PDR001: Novartis Pharmaceuticals
PDR001 (anti-PD-1) is an investigational immunotherapy being developed by Novartis to treat both solid tumors and lymphomas. PDR001 is a type of immunotherapy, it acts by activating the body's own immune system to recognize and fight cancer cells. The drug is being studied in phase II stage of development for the treatment of Nasopharyngeal cancer.
Nasopharyngeal Cancer: Therapeutic Assessment
This segment of the report provides insights about the different NASOPHARYNGEAL CANCER drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Nasopharyngeal Cancer
There are approx. 10+ key companies which are developing the therapies for NASOPHARYNGEAL CANCER. The companies which have their Nasopharyngeal Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.
Phases
This report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Nasopharyngeal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
Molecule Type
Products have been categorized under various Molecule types such as
- Bispecific Antibody
- Peptides
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Nasopharyngeal Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nasopharyngeal Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nasopharyngeal Cancer drugs.
NASOPHARYNGEAL CANCER Report Insights
- Nasopharyngeal Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
NASOPHARYNGEAL CANCER Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Nasopharyngeal Cancer drugs?
- How many Nasopharyngeal Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nasopharyngeal Cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nasopharyngeal Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nasopharyngeal Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Table of Contents
IntroductionExecutive Summary
Nasopharyngeal Cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Nasopharyngeal Cancer - Analytical Perspective
In-depth Commercial Assessment
- NASOPHARYNGEAL CANCER companies' collaborations, Licensing, Acquisition -Deal Value Trends
Nasopharyngeal Cancer Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
Sintililimab: Innovent Biologics (Suzhou) Co. Ltd.
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
PDR001: Novartis Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
SHR-1701: Jiangsu Hengrui Medicine Co.
- Product Description
- Research and Development
- Product Development Activities
Preclinical Stage Products
- Comparative Analysis
Drug Name: Company name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Nasopharyngeal Cancer Key Companies
Nasopharyngeal Cancer Key Products
Nasopharyngeal Cancer - Unmet Needs
Nasopharyngeal Cancer - Market Drivers and Barriers
Nasopharyngeal Cancer - Future Perspectives and Conclusion
Nasopharyngeal Cancer Analyst Views
Nasopharyngeal Cancer Key Companies
AppendixList of Tables
Table 1 Total Products for Nasopharyngeal Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Nasopharyngeal Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Akeso Pharmaceuticals, Inc.
- Atara biotherapeutics
- BeiGene
- Betta Pharmaceuticals Co., Ltd.
- Bristol-Myers Squibb
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Hoffman La Roche
- Incyte Corporation
- innovent Biologics
- Jiangsu HengRui Medicine Co., Ltd.
- Klus Pharma
- Merck Sharp & Dohme Corp.
- Novartis Pharmaceuticals
- Tessa Therapeutics
